In the classical mutant EGFR NSCLC setting, kinase inhibitors remain the gold standard of treatment due to good mutant selectivity [22,23] and capacity to cross the blood-brain barrier to treat brain metastases [32] and combination treatments with mAbs are yet to improve patient outcomes [46]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.